Insitu Biologics: Funding, Investors & Team (Oct 2026)
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and proprietary treatments using its Matrix BioHydrogel. The company's platform develops and manufactures implantable time release products composed of its proprietary tunable and bio-polymeric hydro-gel by using hard particulates in soft matrix, enabling patients to get relieve from peri-operative regional pain by a long-lasting and long-acting non-opiate painkiller.
Insitu Biologics has raised $5.3M across 2 funding rounds on record, the most recent a Convertible Note of $1.3M announced in Aug 2026.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Insitu Biologics Company Profile and Key Stats
Latest funding round on record: Aug 2026.
Insitu Biologics Funding Rounds
Insitu Biologics raised $4.0M in an undisclosed round announced in Dec 2025.
8 months later, a Convertible Note of $1.3M was announced in Aug 2026.
Insitu Biologics Investors
Insitu Biologics Founders and Leadership Team
Contact details for the Insitu Biologics team: 2 of 2 have an email address on file, 2 have a LinkedIn profile.
Start 14-day free trial →Insitu Biologics Funding Compared to Other Biotechnology Startups
Insitu Biologics' latest round of $1.3M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Insitu Biologics in Biotechnology and Minnesota City
Companies Similar to Insitu Biologics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Insitu Biologics Funding FAQs
What does Insitu Biologics do?
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and proprietary treatments using its Matrix BioHydrogel. The company's platform develops and manufactures implantable time release products composed of its proprietary tunable and bio-polymeric hydro-gel by using hard particulates in soft matrix, enabling patients to get relieve from peri-operative regional pain by a long-lasting and long-acting non-opiate painkiller.
How much funding has Insitu Biologics raised?
Insitu Biologics has raised $5.3M across 2 rounds on record. The most recent is a Convertible Note of $1.3M announced in Aug 2026.
When did Insitu Biologics last raise funding?
Insitu Biologics' most recent funding round on record is a Convertible Note of $1.3M, announced in Aug 2026.
Who has invested in Insitu Biologics?
Investors on record for Insitu Biologics include Manhattan Street Fund.
Who founded Insitu Biologics?
FundedIQ lists Bill Taylor (Founder) at Insitu Biologics.
Who is the CEO of Insitu Biologics?
Dan Halpern is listed as CEO at Insitu Biologics.
Where is Insitu Biologics headquartered?
Insitu Biologics is based in Minnesota City, Minnesota, United States.
How many employees does Insitu Biologics have?
Insitu Biologics is in the 11-50 employee band.
When was Insitu Biologics founded?
Insitu Biologics was founded in 2014.
How does Insitu Biologics' funding compare to other Biotechnology startups?
Insitu Biologics' latest round of $1.3M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Insitu Biologics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Insitu Biologics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.